Latest & greatest articles for migraine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on migraine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on migraine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for migraine

1. One-year sustained efficacy of erenumab in episodic migraine: Results of the STRIVE study (Full text)

One-year sustained efficacy of erenumab in episodic migraine: Results of the STRIVE study One-year sustained efficacy of erenumab in episodic migraine: Results of the STRIVE study - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Get the latest public health information from CDC (...) there aren't any new results Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Neurology Actions . 2020 Aug 4;95(5):e469-e479. doi: 10.1212/WNL.0000000000010019. Epub 2020 Jul 7. One-year sustained efficacy of erenumab in episodic migraine: Results of the STRIVE study

2020 EvidenceUpdates PubMed abstract

2. Effect of fremanezumab on quality of life and productivity in patients with chronic migraine (Full text)

Effect of fremanezumab on quality of life and productivity in patients with chronic migraine Effect of fremanezumab on quality of life and productivity in patients with chronic migraine - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Get the latest public health information from (...) in patients with chronic migraine , , , , , Affiliations Expand Affiliations 1 From the Montefiore Headache Center (R.B.L.), Albert Einstein College of Medicine (R.B.L., D.C.B.), Bronx, NY; and Teva Pharmaceutical Industries Ltd. (J.M.C., S.K.G., R.Y., P.P.Y.), West Chester, PA. Richard.Lipton@einstein.yu.edu. 2 From the Montefiore Headache Center (R.B.L.), Albert Einstein College of Medicine (R.B.L., D.C.B.), Bronx, NY; and Teva Pharmaceutical Industries Ltd. (J.M.C., S.K.G., R.Y., P.P.Y.), West Chester

2020 EvidenceUpdates PubMed abstract

3. Onabotulinumtoxin Type A reconstitution with preserved versus preservative-free saline in chronic migraine (B-RECON). A randomised, double-blind trial

Onabotulinumtoxin Type A reconstitution with preserved versus preservative-free saline in chronic migraine (B-RECON). A randomised, double-blind trial Onabotulinumtoxin Type A reconstitution with preserved versus preservative-free saline in chronic migraine (B-RECON). A randomised, double-blind trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features (...) : 10.1111/ijcp.13522. Epub 2020 Aug 2. Onabotulinumtoxin Type A reconstitution with preserved versus preservative-free saline in chronic migraine (B-RECON). A randomised, double-blind trial , , , , Affiliations Expand Affiliations 1 Department of Neurology, SUNY Upstate Medical University, Syracuse, NY, USA. 2 Center for Research and Evaluation, SUNY Upstate Medical University, Syracuse, NY, USA. PMID: 32350975 DOI: Item in Clipboard Onabotulinumtoxin Type A reconstitution with preserved versus

2020 EvidenceUpdates

4. Fremanezumab (Ajovy) - migraine

Fremanezumab (Ajovy) - migraine Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs written for approved after September 1, 2012 will be updated

2020 Health Canada - Drug and Health Product Register

5. Intravenous metoclopramide versus dexketoprofen trometamol versus metoclopramide+ dexketoprofen trometamol in acute migraine attack in the emergency department: A randomized double-blind controlled trial

Intravenous metoclopramide versus dexketoprofen trometamol versus metoclopramide+ dexketoprofen trometamol in acute migraine attack in the emergency department: A randomized double-blind controlled trial Intravenous Metoclopramide Versus Dexketoprofen Trometamol Versus metoclopramide+ Dexketoprofen Trometamol in Acute Migraine Attack in the Emergency Department: A Randomized Double-Blind Controlled Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage (...) Migraine Attack in the Emergency Department: A Randomized Double-Blind Controlled Trial , , , Affiliations Expand Affiliations 1 Department of Emergency Medicine, Adiyaman University Training and Research Hospital, Adiyaman, Turkey. 2 Department of Emergency Medicine, Adiyaman University Training and Research Hospital, Adiyaman, Turkey. Electronic address: umutgulacti@gmail.com. PMID: 32359776 DOI: Item in Clipboard Intravenous Metoclopramide Versus Dexketoprofen Trometamol Versus metoclopramide

2020 EvidenceUpdates

6. Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2 (Full text)

Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2 Efficacy and Safety of Eptinezumab in Patients With Chronic Migraine: PROMISE-2 - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health National Library of Medicine National Center for Biotechnology Information Show account info (...) Permalink Copy Page navigation Neurology Actions . 2020 Mar 31;94(13):e1365-e1377. doi: 10.1212/WNL.0000000000009169. Epub 2020 Mar 24. Efficacy and Safety of Eptinezumab in Patients With Chronic Migraine: PROMISE-2 , , , , , , , , Affiliations Expand Affiliations 1 From the Montefiore Headache Center (R.B.L.); Department of Neurology (R.B.L.), Albert Einstein College of Medicine, Bronx, NY; NIHR-Wellcome Trust King's Clinical Research Facility (P.J.G.), SLaM Biomedical Research Centre, King's College

2020 EvidenceUpdates PubMed abstract

7. Enhanced mindfulness-based stress reduction in episodic migraine: a randomized clinical trial with magnetic resonance imaging outcomes

Enhanced mindfulness-based stress reduction in episodic migraine: a randomized clinical trial with magnetic resonance imaging outcomes Enhanced Mindfulness-Based Stress Reduction in Episodic Migraine: A Randomized Clinical Trial With Magnetic Resonance Imaging Outcomes - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National (...) RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Pain Actions . 2020 Mar 13. doi: 10.1097/j.pain.0000000000001860. Online ahead of print. Enhanced Mindfulness-Based Stress Reduction in Episodic Migraine: A Randomized Clinical Trial With Magnetic Resonance Imaging Outcomes , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Department of Neural and Pain Sciences, School of Dentistry, University

2020 EvidenceUpdates

8. Fremanezumab for preventing migraine

Fremanezumab for preventing migraine Fremanezumab for preventing migraine T echnology appraisal guidance Published: 3 June 2020 www.nice.org.uk/guidance/ta631 © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Your responsibility Your responsibility The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health (...) system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Fremanezumab for preventing migraine (TA631) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 33Contents Contents 1 Recommendations 4 2 Information about fremanezumab 6 Marketing authorisation indication 6 Dosage in the marketing authorisation 6 Price 6 3 Committee discussion 7 The condition 7

2020 National Institute for Health and Clinical Excellence - Technology Appraisals

9. Acupuncture versus propranolol in migraine prophylaxis: an indirect treatment comparison meta-analysis. (Abstract)

Acupuncture versus propranolol in migraine prophylaxis: an indirect treatment comparison meta-analysis. Propranolol is recommended as first-line treatment for preventing migraine attacks; acupuncture has not been compared with propranolol in a head-to-head trial.To compare acupuncture with propranolol using indirect treatment comparison meta-analysis.We searched MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials (CENTRAL). Randomized controlled trials comparing acupuncture (...) or propranolol with sham acupuncture, placebo, waiting-list control or usual care were included. We extracted information from the included trials using a standardized extraction form. The primary outcome was migraine episodes. The secondary outcomes included migraine days, migraine frequency, and adverse events.We included 19 RCTs (n = 3656) after screening 1078 articles. The analysis showed that acupuncture had a significant advantage over propranolol in reducing migraine episodes over a 4-week period (SMD

2020 Journal of neurology

10. Serotonin-norepinephrine reuptake inhibitors for the prevention of migraine and vestibular migraine: a systematic review and meta-analysis. (Abstract)

Serotonin-norepinephrine reuptake inhibitors for the prevention of migraine and vestibular migraine: a systematic review and meta-analysis. The role of serotonin-norepinephrine reuptake inhibitors (SNRIs) in migraine prophylaxis has not been completely established. Current treatments for vestibular migraine (VM) are based on scarce evidence. We aimed to perform an updated review focusing on the efficacy and tolerability of SNRIs for migraine and VM prevention.We searched the PubMed, Web (...) of Science, and Cochrane Library databases for relevant studies. The primary outcome was migraine frequency. In the case of VM, the Dizziness Handicap Inventory (DHI) scores and Vertigo Severity Scores (VSSs) were extracted.Six randomized controlled trials involving 418 patients were analyzed. Patients receiving SNRIs had fewer migraine days than those receiving a placebo (standardized mean difference -0.38, 95% CI -0.76 to -0.01, p=0.04). The effects of SNRIs and other active drugs were comparable

2020 Regional Anesthesia and Pain Medicine

11. Psychological Sleep Interventions for Migraine and Tension-Type Headache: A Systematic Review and Meta-Analysis. (Full text)

Psychological Sleep Interventions for Migraine and Tension-Type Headache: A Systematic Review and Meta-Analysis. Disordered sleep, poor sleep quality, and insufficient or excessive sleep duration are known triggers of primary and secondary headaches. Given this, it is plausible that improving sleep will subsequently reduce headache activity. We report a systematic review of the literature, examining studies utilising psychological sleep interventions for the treatment of migraine and tension

2020 Scientific reports PubMed abstract

12. The impact of external trigeminal nerve stimulator (e-TNS) on prevention and acute treatment of episodic and chronic migraine: A systematic review. (Full text)

The impact of external trigeminal nerve stimulator (e-TNS) on prevention and acute treatment of episodic and chronic migraine: A systematic review. The aim of this systematic review was to analyze the effectiveness and safety of the external trigeminal nerve stimulator (eTNS) for the prevention and acute treatment of migraine attacks in episodic and chronic migraine patients.We have conducted a systematic literature search in four databases that yielded 433 citations and additional seven (...) citations were found via hand-search. Two randomised placebo-controlled trials and five prospective case series were included in the analysis.Concerning prevention, statistically significant differences were found with respect to reduction of migraine attacks (0.67 less migraine attacks per month), migraine days (1.74 less migraine days per month), headache days (2.28 less headache days per month), and acute antimigraine drug intake (4.24 less instances of acute drug intake per month). Concerning acute

2020 Journal of the neurological sciences PubMed abstract

13. CGRP monoclonal antibody for preventive treatment of chronic migraine: An update of meta-analysis. (Full text)

CGRP monoclonal antibody for preventive treatment of chronic migraine: An update of meta-analysis. CGRP monoclonal antibody (mAb) is a promising preventive treatment for episodic migraine and has been approved by US FDA recently. But the treatments for chronic migraine are rare. Therefore, we performed meta-analysis to assess the efficacy and safety of CGRP mAbs in preventing chronic migraine.Database including Cochrane Library and PubMed were systematically searched for randomized controlled (...) trials (RCTs) which are about CGRP mAb in preventing treatment of chronic migraine. Evaluating the bias and quality of RCTs was carried out according to the Cochrane collaboration's tool for assessing risk of bias. The data analysis was carried out by reviewer manager 5.2.Totally, 6 articles enrolled in the present meta-analysis, including 4 independent clinical trials and 3,166 patients. After pooled analysis, it indicated that CGRP mAb improved 50% responder rate (OR = 2.42, 95% CI = [2.04, 2.87

2020 Brain and behavior PubMed abstract

14. Migraine, low-dose combined hormonal contraceptives, and ischemic stroke in young women: a systematic review and suggestions for future research. (Abstract)

Migraine, low-dose combined hormonal contraceptives, and ischemic stroke in young women: a systematic review and suggestions for future research. Introduction: Migraine and combined hormonal contraceptives (CHCs) increase the risk of ischemic stroke in young women; however, the contribution of low-dose (<50 μg ethinylestradiol) CHCs to the risk of ischemic stroke in young women with migraine is not well defined.Areas covered: The authors performed a systematic review of observational studies (...) indexed in PubMed and Scopus from inception to 22 May 2019, reporting the effect sizes of ischemic stroke in women with migraine using low-dose CHCs compared with those without migraine not using CHCs. All the four included case-control studies, including a total of 12,256 women, reported increased odds of ischemic stroke in women with migraine and low-dose CHC use compared with those without migraine not using CHCs. A meta-analysis was not feasible due to significant heterogeneity.Expert opinion

2020 Expert review of neurotherapeutics

15. Herbal treatments for migraine: A systematic review of randomised-controlled studies. (Abstract)

Herbal treatments for migraine: A systematic review of randomised-controlled studies. Herbal treatments are often used as a treatment for migraine. Therefore, an evaluation of their safety and efficacy is important. Based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, and Cochrane Collaboration's tool for assessing the risk of bias, a systematic literature review of randomised, controlled human trials assessing the effects of herbal treatments delivered (...) as a single ingredient for the acute or prophylactic treatment of migraine were conducted. Studies were identified through electronic database searches on Medline (Pubmed), Cochrane Library, Scopus, and CINAHL. Nineteen studies were identified examining the effects on migraine of feverfew, butterbur, curcumin, menthol/peppermint oil, coriander, citron, Damask rose, chamomile, and lavender. Overall, findings on the efficacy of feverfew were mixed and there was positive, albeit limited evidence

2020 Phytotherapy research : PTR

16. Economic Evaluation of Treatments for Migraine: An Assessment of the Generalizability Following a Systematic Review. (Abstract)

Economic Evaluation of Treatments for Migraine: An Assessment of the Generalizability Following a Systematic Review. All health economics reviews on chronic and episodic migraine published to date underline the heterogeneity of results. Currently, the need for the generalizability of economic evaluations across different jurisdictions is considered a key issue to avoid unnecessary overlaps and to minimize the time to reimbursement decisions.The aim of this study was to review the economic (...) evaluations on the prophylaxis and treatments for migraine published in the previous 10 years (since 2009) and to perform a critical assessment of their generalizability.We searched PubMed, EMBASE, and EconLit databases. Articles underwent a three-stage selection process. To assess the level of generalizability, we used the checklist implemented by Augustovski et al. Studies were classified as: (1) generalizable; (2) transferable; and (3) context specific.In total, 227 articles were identified after

2020 PharmacoEconomics

17. Serotonin and Neuropeptides in Blood From Episodic and Chronic Migraine and Cluster Headache Patients in Case-Control and Case-Crossover Settings: A Systematic Review and Meta-Analysis. (Abstract)

Serotonin and Neuropeptides in Blood From Episodic and Chronic Migraine and Cluster Headache Patients in Case-Control and Case-Crossover Settings: A Systematic Review and Meta-Analysis. The aim of this systematic review and meta-analysis (SR-MA) was to identify signaling molecule profiles and blood-derived biomarkers in migraine and cluster headache (CH) patients.Currently no migraine and CH valid biomarkers are available. Blood tests based on biomarker profiles have been used to gather (...) intestinal peptide) and the quantitative synthesis on 5-HT and CGRP (≥5 comparisons available). The meta-analysis was conducted using standard and 3-level random effect models.Fifty-four eligible studies were identified (87.0% migraine, 9.3% CH, 3.7% migraine, and CH), and 2768 headache patients and 1165 controls included. Comparable fluctuations of 5-HT, CGRP, ET-1, PACAP-38, and SP in blood were generally observed between migraine and CH. Significant findings were observed for some subgroups and strata

2020 Headache

18. Predictors of episodic migraine transformation to chronic migraine: A systematic review and meta-analysis of observational cohort studies. (Abstract)

Predictors of episodic migraine transformation to chronic migraine: A systematic review and meta-analysis of observational cohort studies. An estimated 2.5-3.1% of people with episodic migraine develop chronic migraine in a year. Several risk factors are associated with an increased risk for this transformation. We conducted a systematic review and meta-analysis to provide quantitative and qualitative data on predictors of this transformation.An electronic search was conducted for published (...) , prospective, cohort studies that reported risk factors for chronic migraine among people with episodic migraine. Risk of bias was assessed using the Newcastle-Ottawa Quality Assessment Scale. Quality of evidence was determined according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) guidelines. Effect estimates were retrieved and summarized using risk ratios.Of 5695 identified publications, 11 were eligible for inclusion. The pooled analysis (GRADE system) found "high

2020 Cephalalgia : an international journal of headache

19. Clinical Efficacy and Safety of Electroacupuncture in Migraine Treatment: A Systematic Review and Network Meta-Analysis. (Abstract)

Clinical Efficacy and Safety of Electroacupuncture in Migraine Treatment: A Systematic Review and Network Meta-Analysis. Considering the heavy burden of migraine, it is essential to update insufficient and/or outdated clinical evidence supporting electroacupuncture (EA) in migraine therapy. In this study, a literature search of seven medical databases was performed. After data extraction and quality evaluation, 13 randomized controlled trials, including 1559 patients, were assessed (...) effects. Sensitivity analysis confirmed the stability of the studies included in this research. EA is one of several effective treatments for migraine pain symptoms, and, to some extent, anxiety and depression. Nevertheless, multi-center studies with large sample sizes and/or well-designed randomized controlled trials (RCTs) will be needed in the future.

2020 The American journal of Chinese medicine

20. Pyridoxine, folate and cobalamin for migraine: A Systematic Review. (Abstract)

Pyridoxine, folate and cobalamin for migraine: A Systematic Review. There is a possible relationship between migraine and hypercoagulability inducing factors, such as hyperhomocysteinemia. In this context, homocysteine(Hcy) lowering vitamins(B6-folate-B12) may prove beneficial in the management-prophylaxis of migraine. We performed a systematic literature search in order to retrieve studies assessing the supplementation of B6, folate and B12 (alone or as adjunctive therapies) to migraine (...) patients, as well as patients suffering from other primary headache disorders. MEDLINE, EMBASE, CENTRAL, Google Scholar, trial registries and OpenGrey were searched. Twelve relevant articles were retrieved. The management of acute migraine attacks with Hcy lowering vitamins has not provided promising results (one Randomized Controlled Trial-RCT-, one prospective uncontrolled trial). On the contrary, significant benefits were registered for the use of B6 alone, in combination with folate

2020 Acta neurologica Scandinavica